Abstract
A recent review1 of the epidemiology of randomized clinical trials indicates very slow acceptance of this approach to evaluation of new medical treatments. If the proportion of randomized trials among therapeutic studies in gastroenterology continues to increase at the rate observed over the past decade, the reviewers estimate that the format will have taken over completely by the year 2010 provided the increase is exponential, and in about 700 years if it is linear. I write to suggest that a law, similar to Gresham's Law—cheap money will drive out dear money—operates in these matters.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
